KRAS G12C mutation
2 drugsPredictive biomarker for patient selection in 4 indications
2
Approved Drugs
4
Indications
2
Companies
KRAS G12C mutation is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 4 indications including KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Explore the targeted therapies, indications, testing methods, and companies developing KRAS G12C mutation drugs below.
Search KRAS G12C mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting KRAS G12C mutation
KRAS G12C mutation Indications
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer KRAS G12C-mutated metastatic colorectal cancer